Bartu BADAK, Olga Meltem AKAY, Göknur YORULMAZ, Muzaffer BİLGİN, Elif Sevil ALAGÜNEY, Nur KEBAPÇI, Eren GÜNDÜZ, Belgin EFE, Aysen AKALIN, Betül AYDIN BUYRUK, Ahmet Toygar KALKAN

Effect of hyperparathyroidism on coagulation: a global assessment by modified rotation thromboelastogram (ROTEM)

Background/aim: Hyperparathyroidism is an endocrine disorder characterized by hypercalcemia. Because of calcium’s effects on parathyroid glands, bone, intestines, and kidneys, it has an important place in homeostasis. The results of studies regarding hyperparathyroidism hemostasis are conflicting. Thromboelastography helps to evaluate all steps of hemostatic system. Our aim in this study was to investigate the possible role of hemostatic mechanisms in the development of thrombosis in hyperparathyroid patients with the modified rotation thromboelastogram (ROTEM). Materials and methods: Twenty-two patients with primary hyperparathyroidism (PHPT) and 20 healthy controls were involved. This study was conducted in Eskisehir Osmangazi University Faculty of Medicine, Endocrinology and Hematology clinics for 2 years. The complete blood count, fibrinogen, D-dimer levels, prothrombin time, activated prothrombin time, and ROTEM parameters [clot formation time (CFT), clotting time (CT), and maximum clot formation (MCF)] were determined by two activated tests, INTEM and EXTEM analyses. A thromboelastographic evaluation was performed in the preoperative and postoperative (3 months after surgery) periods. Results: In INTEM assay, the CT (p = 0.012) and CFT (p = 0.07) values were increased in preoperative PHPT patients compared with the control group. Although there was a decrease in the postoperative CT and CFT values, no statistical difference was found. Conclusion: The prolongation of the CT and CFT values were consistent with a hypocoagulable state in patients with PHPT. Hyperparathyroidism causes a hypocoagulable state that can be successfully assessed by ROTEM. Hemostatic changes, do not seem to have an effect on increased cardiovascular mortality.Key words: Hyperparathyroidism, coagulation, thromboelastogram, ROTEM

PDF

___

1. Hedback G, Tisell LE, Bengtsson BA, Hedman I, Oden A. Premature death in patients operated on for PHPT. World Journal of Surgery 1990; 14: 829- 835. doi: 10.1007/BF01670531.
2. Walker MD, Silverberg SJ. Primary hyperparathyroidism. Nature Reviews Endocrinology 2018; 14 (2): 115-125. doi: 10.1038/nrendo.2017.104.
3. Erem C, Kocak M, Hacihasanoglu A, Yılmaz M, Saglam F et al. Blood coagulation; fibrinolysis and lipid profile in patients with primary hyperparathyroidism: increased plasma factor VII and X activities and D-dimer levels. Experimental and Clinical Endocrinology & Diabetes 2008; 116: 619- 624. doi: 10.1055/s-2008-1065365.
4. Erem C, Kocak M, Nuhoglu I, Yılmaz M, Ucuncu O. Increased plasma activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism. European Journal of Endocrinology 2009; 160: 863-868. doi: 10.1530/EJE-09-0069.
5. Franchello A, Camandona M, Gasparri G. Acute hyperparathyroidism and vascular thrombosis: an unrecognized association. Journal of Endocrinological Investigation 2010; 33 (9): 683. doi: 10.1007/BF03346669.
6. Farahnak P, Lärfars G, Sten-Linder M, Nilsson IL. Mild primary hyperparathyroidism: vitamin D deficiency and cardiovascular risk markers. Journal of Clinical Endocrinology and Metabolism 2011; 96 (7): 2112-2118. doi: 10.1210/jc.2011- 0238.
7. Anderson JL, Vanwoerkum R, Horne BD, Bair TL, May HT et al. Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors? American Heart Journal 2011; 162: 331-339. doi: 10.1016/j.ahj.2011.05.005.
8. Boas WWV, Oliveira CB, Maximo TA. Thromboelastographic profile of patients with hyperparathyroidism secondary to chronic kidney failure submitted to total parathyroidectomy. Case Series Open Journal of Anesthesiology 2013; 3: 363-366.
9. Koufakis T, Antonopoulou V, Grammatiki M, Karras SN, Ajjan R et al. The relationship between primary hyperparathyroidism and thrombotic events: report of three cases and a review of potential mechanisms. International Journal of HematologyOncology and Stem Cell Research 2018; 1: 12 (3): 175-180.
10. Bilezikian JP, Silverberg SJ. Clinical practice. Asymptomatic primary hyperparathyroidism. New England Journal of Medicine 2004; 350 (17): 1746–1751. doi: 10.1056/NEJMcp032200.
11. Walker GL, Williamson PM, Ravich RB, Roche J. Hypercalcaemia associated with cerebral vasospasm causing infarction. Journal of Neurology, Neurosurgery, and Psychiatry 1980; 43 (5): 464-467. doi: 10.1136/jnnp.43.5.464.
12. Siesjo B. The role of calcium in cell death. In: Price DL, Thoenen H, Aguayo AJ, editors. Neurodegenerative disorders; mechanisms and prospects for therapy. Chichester: John Wiley & Sons Ltd; 1991. pp. 35-59.
13. Akay OM. The double hazard of bleeding and thrombosis in hemostasis from a clinical point of view: a global assessment by rotational thromboelastometry (ROTEM). Clinical and Applied Thrombosis/Hemostasis 2018; 24 (6): 850-858. doi: 10.1177/1076029618772336.
14. Targher G, Pichiri I, Zoppini G, Bonora E, Chonchol M. Hemostatic and fibrinolytic abnormalities in endocrine diseases: a narrative review. Seminars in Thrombosis and Hemostasis 2009; 35 (7) :605-612. doi: 10.1055/s-0029- 1242714.
15. Lundgren E, Lind L, Palme´r M, Jakobsson S, Ljunghall S et al. Increased cardiovascular mortality and normalized serum calcium in patients with mild hypercalcemia followed up for 25 years. Surgery 2001; 130 (6): 978–985. doi: 10.1067/msy.2001.118377.
16. Hedbäck G, Odén A. Persistent disease after surgery for primary hyperparathyroidism: the long-term outcome. European Journal of Endocrinology 150 (1): 19-25. doi: 10.1530/eje.0.1500019.
17. Lind L, Jacobsson S, Palmer M, Lithell H, Wengle B et al. Cardiovascular risk factors in primary hyperparathyroidism: a 15-year follow-up of operated and unoperated cases. Journa of Internal Medicine 1991; 230 (1): 29-35. doi: 10.1111/j.1365- 2796.1991.tb00403.x.
18. Chertok-Shacham E, Ishay A, Lavi I, Luboshitzky R. Biomarkers of hypercoagulability and inflammation in primary hyperparathyroidism. Medical Science Monitor 2008; 14: CR628–632
19. Li ZL, Chen XM, Yang LC, Deng XL, Fu SH et al. Effects of extracellular calcium concentration on platelets aggregation, coagulation indices and thromboelastography. Zhonghua Yi Xue Za Zhi 2010;90: 1547-1550.
20. Yorulmaz G, Akalın A, Akay OM, Şahin G, Bal C. The Effect of hyperparathyroid state on platelet functions and bone loss. Turkish Journal of Hematology; 1: 33 (4): 293-298. doi: 10.4274/tjh.2015.0087.
21. Elbers L, Wijnberge M, Meijers J, Poland D, Fliers E et al. Coagulation and fibrinolysis in hyperparathyroidism secondary to vitamin D deficiency. Endocrine Connections 2018; 7 (2): 325-333. doi: 10.1530/EC-17-0249.
22. Bilezikian JP. Primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 2018; 1; 103 (11): 3993-4004. doi: 10.1210/jc.2018-01225.
23. Press DM, Siperstein AE, Berber E, Shin JJ, Metzger R et al. The prevalence of undiagnosed and unrecognized primary hyperparathyroidism: a population-based analysis from the electronic medical record. Surgery 2013; 154 (6): 1232-1238. doi: 10.1016/j.surg.2013.06.051.
24. Yeh MW, Ituarte PH, Zhou HC, Nishimoto S, Liu IL et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. The Journal of Clinical Endocrinology and Metabolism 2013; 98 (3): 1122-1129. doi: 10.1210/jc.2012-4022.